These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Leaky lessons learned: Efflux prone dopamine transporter variant reveals sex and circuit specific contributions of D2 receptor signalling to neuropsychiatric disease. Mayer FP; Stewart A; Blakely RD Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):206-218. PubMed ID: 37987120 [TBL] [Abstract][Full Text] [Related]
4. The rare DAT coding variant Val559 perturbs DA neuron function, changes behavior, and alters in vivo responses to psychostimulants. Mergy MA; Gowrishankar R; Gresch PJ; Gantz SC; Williams J; Davis GL; Wheeler CA; Stanwood GD; Hahn MK; Blakely RD Proc Natl Acad Sci U S A; 2014 Nov; 111(44):E4779-88. PubMed ID: 25331903 [TBL] [Abstract][Full Text] [Related]
5. Is dopamine transporter-mediated dopaminergic signaling in the retina a noninvasive biomarker for attention-deficit/ hyperactivity disorder? A study in a novel dopamine transporter variant Val559 transgenic mouse model. Dai H; Jackson CR; Davis GL; Blakely RD; McMahon DG J Neurodev Disord; 2017 Dec; 9(1):38. PubMed ID: 29281965 [TBL] [Abstract][Full Text] [Related]
9. Functional coding variation in the presynaptic dopamine transporter associated with neuropsychiatric disorders drives enhanced motivation and context-dependent impulsivity in mice. Davis GL; Stewart A; Stanwood GD; Gowrishankar R; Hahn MK; Blakely RD Behav Brain Res; 2018 Jan; 337():61-69. PubMed ID: 28964912 [TBL] [Abstract][Full Text] [Related]
10. Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder. Chen R; Ferris MJ; Wang S Pharmacol Ther; 2020 Sep; 213():107583. PubMed ID: 32473160 [TBL] [Abstract][Full Text] [Related]
11. Kappa Opioid Receptor Antagonism Restores Phosphorylation, Trafficking and Behavior induced by a Disease Associated Dopamine Transporter Variant. Mayer FP; Stewart A; Varman DR; Moritz AE; Foster JD; Owens AW; Areal LB; Gowrishankar R; Velez M; Wickham K; Phelps H; Katamish R; Rabil M; Jayanthi LD; Vaughan RA; Daws LC; Blakely RD; Ramamoorthy S bioRxiv; 2024 May; ():. PubMed ID: 37205452 [TBL] [Abstract][Full Text] [Related]
12. Anomalous dopamine release associated with a human dopamine transporter coding variant. Mazei-Robison MS; Bowton E; Holy M; Schmudermaier M; Freissmuth M; Sitte HH; Galli A; Blakely RD J Neurosci; 2008 Jul; 28(28):7040-6. PubMed ID: 18614672 [TBL] [Abstract][Full Text] [Related]
13. Dopamine D3 autoreceptor inhibition enhances cocaine potency at the dopamine transporter. McGinnis MM; Siciliano CA; Jones SR J Neurochem; 2016 Sep; 138(6):821-9. PubMed ID: 27393374 [TBL] [Abstract][Full Text] [Related]
14. The Atypical MAP Kinase SWIP-13/ERK8 Regulates Dopamine Transporters through a Rho-Dependent Mechanism. Bermingham DP; Hardaway JA; Refai O; Marks CR; Snider SL; Sturgeon SM; Spencer WC; Colbran RJ; Miller DM; Blakely RD J Neurosci; 2017 Sep; 37(38):9288-9304. PubMed ID: 28842414 [TBL] [Abstract][Full Text] [Related]
15. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422 [TBL] [Abstract][Full Text] [Related]
16. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. Dickinson SD; Sabeti J; Larson GA; Giardina K; Rubinstein M; Kelly MA; Grandy DK; Low MJ; Gerhardt GA; Zahniser NR J Neurochem; 1999 Jan; 72(1):148-56. PubMed ID: 9886065 [TBL] [Abstract][Full Text] [Related]